Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice

Journal of Clinical Investigation

Volumn 121, Issue 8, 2011, Pages 3220-3232

  Wang, Hongwei ^a   Venkatesh, Madhukumar ^a   Li, Hao ^a   Goetz, Regina ^b   Mukherjee, Subhajit ^a   Biswas, Arunima ^a   Zhu, Liang ^a   Kaubisch, Andreas ^a   Wang, Lei ^c   Pullman, James ^d   Whitney, Kathleen ^d   Kuro o, Makoto ^c   Roig, Andres I ^e   Shay, Jerry W ^e   Mohammadi, Moosa ^b   Mani, Sridhar ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; PREGNANE X RECEPTOR; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; COLON CANCER; CONTROLLED STUDY; CRYPT CELL; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; FIBROBLAST GROWTH FACTORS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHENOTYPE; PLASMIDS; RECEPTORS, STEROID;

EID: 79960980435     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41514     Document Type: Article

References (68)

1. Pasini F, Pelosi G, De Manzoni G, Rosti G. Highdose chemotherapy in small cell lung cancer. Tumori. 2002;88(3):179-186. (Pubitemid 34875443)
2. Ledermann JA. Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2008;18 suppl 1:53-58. (Pubitemid 351389056)
3. Vogl DT, Stadtmauer EA. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant. 2006;37(11):985-987.
4. Seidman AD. Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol. 2003;21(4):577-579. (Pubitemid 46621886)
5. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5(9):744-749. (Pubitemid 41486367)
6. Blagosklonny MV. Cell immortality and hallmarks of cancer. Cell Cycle. 2003;2(4):296-299.
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275-284. (Pubitemid 40488633)
8. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294(5548):1866-1870. (Pubitemid 33101573)
9. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687-702. (Pubitemid 35191629)
10. Blumberg B, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998;12(20):3195-3205. (Pubitemid 28496264)
11. Mani S, et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by non-taxane microtubule-stabilizing agents. Clin Cancer Res. 2005;11(17):6359-6369. (Pubitemid 41262968)
12. Kliewer SA, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998;92(1):73-82. (Pubitemid 28053299)
13. Mikamo E, Harada S, Nishikawa J, Nishihara T. Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol Appl Pharmacol. 2003;193(1):66-72. (Pubitemid 37373766)
14. Kortagere S, Krasowski MD, Reschly EJ, Venkatesh M, Mani S, Ekins S. Evaluation of computational docking to identify PXR agonists in the ToxCast(TM) database. Environ Health Perspect. 2010;118(10):1412-1417.
15. Zhou J, Liu M, Zhai Y, Xie W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol. 2008;22(4):868-880. (Pubitemid 351482823)
16. Chen Y, Tang Y, Wang MT, Zeng S, Nie D. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 2007;67(21):10361- 10367. (Pubitemid 350070811)
17. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol Pharmacol. 2007;72(4):1045-1053. (Pubitemid 47481427)
18. Verma S, Tabb MM, Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer. 2009;9:3.
19. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, Ekins S. Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res. 2009;26(8):1807-1815.
20. Gupta D, et al. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res. 2008;14(17):5332-5340.
21. Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA, Lusis AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J Lipid Res. 2006;47(2):384-392. (Pubitemid 43276924)
22. Wistuba W, Gnewuch C, Liebisch G, Schmitz G, Langmann T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol. 2007;13(31):4230-4235. (Pubitemid 47377162)
23. Schmidt DR, Mangelsdorf DJ. Nuclear receptors of the enteric tract: guarding the frontier. Nutr Rev. 2008;66(10 suppl 2):S88-S97.
24. Desnoyers LR, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008;27(1):85-97.
25. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235-253.
26. Wu X, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A. 2010;107(32):14158-14163.
27. Taylor JGt, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009;119(11):3395-3407.
28. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009;15(6):2058-2066.
29. Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer. 2008;15(1):101-111. (Pubitemid 351449731)
30. Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol. 2010;6(7):363-370.
31. LaPensee EW, Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer. 2010;17(2):R91-R107.
32. LaPensee EW, LaPensee CR, Fox S, Schwemberger S, Afton S, Ben-Jonathan N. Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells. Cancer Lett. 2010;290(2):167-173.
33. Dairkee SH, et al. Bisphenol A induces a profile of tumor aggressiveness in high-risk cells from breast cancer patients. Cancer Res. 2008;68(7):2076- 2080. (Pubitemid 351521778)
34. Xu X, Dailey AB, Talbott EO, Ilacqua VA, Kearney G, Asal NR. Associations of serum concentrations of organochlorine pesticides with breast cancer and prostate cancer in U.S. adults. Environ Health Perspect. 2010;118(1):60-66.
35. Zhu H, et al. Environmental endocrine disruptors promote invasion and metastasis of SKN-SH human neuroblastoma cells. Oncol Rep. 2010;23(1):129-139.
36. Takeshita A, Inagaki K, Igarashi-Migitaka J, Ozawa Y, Koibuchi N. The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J Endocrinol. 2006;190(3):897-902. (Pubitemid 44560263)
37. Diamanti-Kandarakis E, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30(4):293-342.
38. Garg BD, Kovacs K, Blascheck JA, Selye H. Ultrastructural changes induced by pregnenolone nitrile in the rat liver. J Pharm Pharmacol. 1970;22(11):872-873.
39. Dai G, He L, Bu P, Wan YJ. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology. 2008;47(4):1277-1287. (Pubitemid 351547914)
40. Huang H, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene. 2007;26(2):258-268. (Pubitemid 46095736)
41. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102(5):1016-1023. (Pubitemid 28419246)
42. Gonzalez FJ. CYP3A4 and pregnane X receptor humanized mice. J Biochem Mol Toxicol. 2007;21(4):158-162. (Pubitemid 350194374)
43. Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel. 2002;5(1):150-158. (Pubitemid 34453253)
44. Watkins RE, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 2001;292(5525):2329-2333. (Pubitemid 32568055)
45. Moore LB, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem. 2000;275(20):15122-15127. (Pubitemid 30337234)
46. Stover DR, Becker M, Liebetanz J, Lydon NB. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem. 1995;270(26):15591-15597.
47. Xue KX, Gao J. [Study of liver metastasis formation and its mechanism using intrasplenic inoculation of cancer cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1987;9(3):217-222.
48. Thalheimer A, et al. The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer. 2009;9:29.
49. Goetz R, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010;107(1):407-412.
50. Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst. 2004;96(19):1408-1409. (Pubitemid 39429654)
51. Wang H, et al. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol. 2008;22(4):838-857. (Pubitemid 351482821)
52. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol. 2007;292(4):G1114-G1122. (Pubitemid 46557773)
53. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581- 14587.
54. Habano W, et al. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer. 2011;11:81.
55. Yue X, et al. Steroid and Xenobiotic Receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer. Pathol Int. 2010;60(5):400-406.
56. Raynal C, et al. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010;9:46.
57. Jiang H, et al. Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J Gastrointest Surg. 2009;13(10):1831-1838.
58. Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010;66(4):765-771.
59. Kodama S, Negishi M. Pregnane X Receptor PXR Activates the GADD45{beta} Gene, Eliciting the p38 MAPK Signal and Cell Migration. J Biol Chem. 2011;286(5):3570-3578.
60. Ouyang N, et al. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer. 2010;102(12):1753-1761.
61. Takeyama D, et al. Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor. Cancer Sci. 2010;101(2):543-549.
62. van de Winkel A, et al. Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. Histopathology. 2011;58(2):246-253.
63. Conde I, et al. Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. BMC Cancer. 2008;8:174.
64. Rioja J, et al. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma. BJU Int. 2011;107(11):1833-1838.
65. Horig H, et al. A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res. 2001;61(23):8520-8526. (Pubitemid 33131134)
66. Sun D, Melegari M, Sridhar S, Rogler CE, Zhu L. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multigene knockdown. Biotechniques. 2006;41(1):59-63. (Pubitemid 46534903)
67. Ferraris RP, Villenas SA, Diamond J. Regulation of brush-border enzyme activities and enterocyte migration rates in mouse small intestine. Am J Physiol. 1992;262(6 pt 1):G1047-G1059.
68. Weiser MM. Intestinal epithelial cell surface membrane glycoprotein synthesis. II. Glycosyltransferases and endogenous acceptors of the undifferentiated cell surface membrane. J Biol Chem. 1973;248(7):2542-2548.